Felip, E., Garcia‐Vidal, E., Heras, S. C. l., Bernat‐Peguera, A., Cirauqui, B., Bergamino, M., . . . Margelí, M. Immune‐based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2– breast cancer. Wiley.
Chicago Style (17th ed.) CitationFelip, Eudald, et al. Immune‐based Transcriptomic Signature Predicts CDK4/6 Inhibitor Efficacy in HR+/HER2– Breast Cancer. Wiley.
MLA (9th ed.) CitationFelip, Eudald, et al. Immune‐based Transcriptomic Signature Predicts CDK4/6 Inhibitor Efficacy in HR+/HER2– Breast Cancer. Wiley.
Warning: These citations may not always be 100% accurate.